The proposed Project includes a complex interplay of both microbicide product development with three classes of novel microbicide candidates, as well as microbicide science advancement in which the three classes of active microbicides will be utilized as tools to better understand how an effective microbicide must act. The product development components consist of three classes of compounds with well documented microbicide potential that may be developed as single or combination agents utilizing gels and/or intravaginal rings that will allow long lasting microbicides to be developed and deployed. We believe the potential advancements in product development (new agents, long lasting delivery technology) and microbicide science (pharmacodynamics, in vitro and ex vivo modeling, effects of seminal and vaginal fluids, acceptability testing methods for long lasting and combination products) make this proposal both inherently novel and important to the field of microbicide science in regard to the development of the next generation of microbicide products. In whole, the Project also provides a new model for the performance of Core functions by adding important assay development objectives to improve the ability to effectively prioritize microbicide development. The Administrative Core will play a critical and essential role in ensuring the smooth integration of the various Projects and Cores included in this cooperative agreement research program. The successful performance of this Project requires a high degree of communication and interaction between the various Projects, the Cores, and the Corporate Partner. The Administrative Core will be responsible for managing and enhancing this constructive and synergistic interplay between the participating scientific groups.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI077289-02
Application #
7910674
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
2
Fiscal Year
2009
Total Cost
$49,777
Indirect Cost
Name
Imquest Biosciences
Department
Type
DUNS #
146051664
City
Frederick
State
MD
Country
United States
Zip Code
21704
Gao, Yajing; Katz, David F (2017) Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema. PLoS One 12:e0167696
Funke, Claire; MacMillan, Kelsey; Ham, Anthony et al. (2016) Coupled gel spreading and diffusive transport models describing microbicidal drug delivery. Chem Eng Sci 152:12-20
Gao, Y; Yuan, A; Chuchuen, O et al. (2015) Vaginal deployment and tenofovir delivery by microbicide gels. Drug Deliv Transl Res 5:279-94
Katz, David F; Yuan, Andrew; Gao, Yajing (2015) Vaginal drug distribution modeling. Adv Drug Deliv Rev 92:2-13
Morrow Guthrie, Kate; Vargas, Sara; Shaw, Julia G et al. (2015) The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development. PLoS One 10:e0145642
Rosen, Rochelle K; van den Berg, Jacob J; Vargas, Sara E et al. (2015) Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings. Contraception 92:596-601
Ugaonkar, Shweta R; Clark, Justin T; English, Lexie B et al. (2015) An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission. J Pharm Sci 104:3426-39
van den Berg, Jacob J; Rosen, Rochelle K; Bregman, Dana E et al. (2014) ""Set it and forget it"": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav 18:862-70
Tolley, Elizabeth E; Morrow, Kathleen M; Owen, Derek H (2013) Designing a multipurpose technology for acceptability and adherence. Antiviral Res 100 Suppl:S54-9
Rastogi, Rachna; Teller, Ryan S; Mesquita, Pedro M M et al. (2013) Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. Antiviral Res 100:255-8

Showing the most recent 10 out of 25 publications